postoperative shivering in patients undergoing TURP.
Conditions
Interventions
Intervention 1: Group 1:Patients will receive 75 mg of Bupivacaine (Exir Pharmaceutical, Iran) combined with 1–1.5 cc of Ondansetron (Caspian Tamin Pharmaceutical, Iran) via the neuraxial route. Inter
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
35 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients undergoing TURP referred to Vali-Asr and Amir Al-Momenin Hospitals in Arak. Patients with informed consent for participation in the study. Patients aged 35 to 70 years Patients classified as ASA Class I and II Patients with no cardiovascular, respiratory, or renal diseases. Patients with no history of cerebrovascular accident (CVA). Patients who are not IV drug abusers All patients undergoing spinal anesthesia No allergy to Marcaine, Ondansetron, Pethidine, or Dexmedetomidine.
Exclusion criteria
Exclusion criteria: All patients for whom spinal anesthesia fails during surgery, requiring conversion to general anesthesia. All patients who experience cardiopulmonary arrest for any reason during surgery. All patients who, for any reason, require general anesthesia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The occurrence or absence of shivering in patients. Timepoint: The occurrence of shivering and pain score in patients at 2, 4, 6, and 8 hours postoperatively. Method of measurement: VAS questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRasoul Jafari
Arak University of Medical Sciences
Outcome results
None listed